MDT Stock Recent News

Medtronic remains an attractive investment due to its diversified revenue streams, robust product pipeline and improving margins. MDT's growth is driven by strong performance in Neuroscience, Cardiovascular, and Diabetes care, with significant international revenue growth and a promising product pipeline. Trading below its historical valuation, MDT offers a compelling opportunity for conservative investors seeking quality at a reasonably low price.

The latest rate cut should help Medtronic expand in the AFib, structural heart, robotics, neuromodulation, hypertension and diabetes markets.

Investors continue to be optimistic about Medtronic due to strength in its Neurosurgery portfolio. Yet, mounting expenses pose a threat to the company's margins.

Medtronic plc (NYSE:MDT ) 2024 Wells Fargo Healthcare Conference September 4, 2024 11:35 AM ET Company Participants Geoff Martha - Chairman & CEO Conference Call Participants Larry Biegelsen - Wells Fargo Larry Biegelsen Good afternoon or good morning, and it's about to be good afternoon and welcome to the 2024 Wells Fargo Healthcare Conference. Thank you for helping make this our largest healthcare conference yet.

Geoff Martha, Medtronic CEO, joins 'Money Movers' to discuss the company's quarterly earnings results, where the company's business is toughest, and much more.

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 50 points on Tuesday.

While the pairing of artificial intelligence and healthcare may sound like something straight out of a science fiction movie, there are several avenues through which the high-speed data processing offered by AI can improve patient outcomes. From more precise diagnosis to pandemic modeling, the large-scale algorithmic models we call AI can help the world of medicine immensely.

Dividend stocks are finally cycling back into portfolios after a few years' worth of higher interest rates put fixed-income options ahead of dividend distribution yield for income investors. As those investors circle back toward dividend stocks, a few things have changed about how to best look at the many available offerings – but that's true for most stock segments today.

Now that it's focused on just medical technology and pharmaceuticals, Johnson & Johnson's pace of annual dividend raises could accelerate. Medtronic is the largest publicly traded medical device manufacturer, and it offers a 3.3% yield at recent prices.

Undervalued healthcare stocks are primed for a comeback this year, proving themselves as lucrative investments amidst a revitalized market. With a significant uptick in performance, the S&P 500 Health Care index soared roughly 7% year-to-date (YTD), marking a robust recovery from last year's challenges.